The most recent AACE treatment Guideline put TZD group (the group which actos belongs to) as the first line treatment option for type 2 Diabetic patients with Metabolic Syndrome. Hikma Markets Actos in 13 countries in MENA region (Jordan, Saudi Arabia, Lebanon, Libya, Tunisia, Algeria, UAE, Kuwait, Oman, Yemen, Bahrain, Qatar and Egypt).